Non ST Segment Elevation (NSTEMI) Myocardial Infarction


Article Author:
Hajira Basit
Ahmad Malik


Article Editor:
Martin Huecker


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
5/4/2019 9:20:06 PM

Introduction

Acute coronary syndrome (ACS) can be divided into subgroups of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. ACS carries significant morbidity and mortality and the prompt diagnosis, and appropriate treatment is essential. STEMI diagnosis and management are discussed elsewhere. NSTEMI and Unstable angina are very similar, with NSTEMI having positive cardiac biomarkers. The presentation, diagnosis, and management of NSTEMI are discussed below.[1][2][3]

Etiology

The etiology of NSTEMI varies as there are several potential causes.

Epidemiology

The median age at the time of presentation for ACS in the United States is 68 years. Males outnumber females by a 3:2 ratio. The incidence of ACS in the United States is over 780,000, and of those, approximately 70% will have NSTEMI.

Pathophysiology

ACSs are simply a mismatch in the myocardial oxygen demand and myocardial oxygen consumption. While the cause of this mismatch in STEMI is nearly always coronary plaque rupture resulting thrombosis formation occluding a coronary artery, there are several potential causes of this mismatch in NSTEMI. There may be a flow-limiting condition such as a stable plaque, vasospasm as in Prinzmetal angina, coronary embolism, or coronary arteritis. Non-coronary injury to the heart such as cardiac contusion, myocarditis, or presence of cardiotoxic substances can also produce NSTEMI. Finally, conditions relatively unrelated to the coronary arteries or myocardium itself such as hypotension, hypertension, tachycardia, aortic stenosis, and pulmonary embolism lead to NSTEMI because the increased oxygen demand cannot be met.[4][5]

History and Physical

The “typical” presentation of NSTEMI is a pressure-like substernal pain, occurring at rest or with minimal exertion. The pain generally lasts more than 10 minutes and may radiate to either arm, the neck, or the jaw.  The pain may be associated with dyspnea, nausea or vomiting, syncope, fatigue, or diaphoresis. Sudden onset of unexplained dyspnea with or without associated symptoms is also a common presentation. Risk factors for ACS include male sex, older age, family history of coronary artery disease, diabetes, personal history of coronary artery disease, and renal insufficiency. Atypical symptoms may include a stabbing or pleuritic pain, epigastric or abdominal pain, indigestion, and isolated dyspnea. While all patients presenting with ACS are more likely to present with typical symptoms than atypical symptoms, the likelihood of atypical presentations increases with age over 75, women and those with diabetes, renal insufficiency, and dementia.  

Physical Exam for ACS and NSTEMI is often nonspecific. Clues such as back pain with aortic dissection or pericardial friction rub with pericarditis may point to an alternative diagnosis for a patient’s chest pain, but no such exam finding exists that indicates ACS as the most likely diagnosis. Signs of heart failure should increase concern for ACS but are, again, nonspecific findings.[6][7][8]

Evaluation

History, ECG, and cardiac biomarkers are the mainstays in the evaluation. An ECG should be performed as soon as possible in patients presenting with chest pain or those with a concern for ACS. A normal ECG does not exclude ACS and NSTEMI. ST elevation or anterior ST depression should be considered a STEMI until proven otherwise and treated as such. Findings suggestive of NSTEMI include transient ST elevation, ST depression, or new T wave inversions. ECG should be repeated at predetermined intervals or if symptoms return.

Cardiac troponin is the cardiac biomarker of choice. Troponin is more specific and more sensitive than other biomarkers and becomes elevated relatively early in the disease process. While contemporary cardiac troponin may not be elevated within the first 2 to 4 hours after symptom onset, newer high sensitivity troponin assays have detectable elevations much earlier. It is also true that the amount of troponin released, and therefore the time to elevation, is proportional with infarct size, so it is unlikely to have a negative initial troponin with larger infarcts. Regardless of infarct size, most patients with true ischemia will have elevations in troponin within 6 hours, and negative troponins at this point effectively rule out infarct in most patients.  Most assays use a cutoff value of greater than a 99th percentile as a positive test. In older, contemporary troponin assays, no detectable troponin is reported in most healthy individuals without the disease.  Newer high sensitivity troponin assays often will report a normal detectable range in healthy individuals without the disease. 

Several tools and scores have been developed to assist in the workup of ACS. These tools must be used with caution and in the appropriate context as none have been definitively shown to be superior to clinician judgment. Some common tools available are the TIMI (Thrombolysis In Myocardial Infarction) risk score, the GRACE (Global Registry of Acute Coronary Events) risk score, the Sanchis score, the Vancouver rule, HEART (History, ECG, Age, Risk Factors, and Troponin) score, HEARTS3 score, and Hess prediction rule. The HEART score was specifically developed for emergency department patients and has gained popularity in this setting. 

Diagnosis 

NSTEMI is diagnosed in patients determined to have symptoms consistent with ACS and troponin elevation but without ECG changes consistent with STEMI. Unstable angina and NSTEMI differ primarily in the presence or absence of detectable troponin leak. 

Treatment / Management

Initial management strategies aim to reduce cardiac ischemia and prevent death. Oxygen, aspirin, and nitrates are administered based on initial concern for ACS and prior to definitive diagnosis. Subsequent treatment depends on confirmation of diagnosis or high index of suspicion with or without definitive diagnosis. [1][9][10][11][12]

Oxygen was previously recommended for all patients presenting with concern for ACS, but newer data suggests this strategy may be harmful in patients who otherwise do not warrant supplemental oxygen. Supplemental oxygen is now recommended in patients with oxygen saturation less than 90%, those with respiratory distress, or when high risk features of hypoxemia are present. 

Chewable, non-coated, aspirin 324 mg should be given to all patients who present with concern for ACS unless otherwise contraindicated.  Patients who cannot take aspirin may be given Clopidogrel 300-600 mg or Ticagrelor 180 mg as a loading dose for antiplatelet therapy. 

Patients with ongoing symptoms should receive 0.4 mg sublingual nitroglycerin every 5 minutes for up to three doses or until pain is relieved, unless otherwise contraindicated. Contraindications include recent use of phosphodiesterase inhibitors and hypotension. Nitrates should be used with extreme caution in patients with concern for right sided infarction. Continuous intravenous nitroglycerin should be considered in patients with persistent signs of heart failure or hypertension.

Many patients will present with concern for ACS but will not have positive findings of ischemic ECG changes or positive troponin on initial workup. These patients may be observed with serial ECG and troponin measurements every 3 to 6 hours. Patients also may undergo provocative testing such as the treadmill stress test or myocardial perfusion imaging prior to discharge or within 72 hours. Low risk patients often may be discharged with referral for further outpatient testing after initial ACS is ruled out.

In patients where NSTEMI has been definitively diagnosed or is highly likely, anticoagulation should be initiated. Protocols will vary by institution, so cardiology consultation should be obtained if readily available. This is especially true when there is the possibility of percutaneous intervention, as this may change anticoagulation strategies. Unfractionated heparin with bolus dosing and continuous infusion is commonly used, with most institutions having protocols available. Other strategies may include the use of enoxaparin, bivalirudin, fondaparinux, and dual antiplatelet therapies. Fibrinolytic therapies should not be used in NSTEMI. 

When NSTEMI has been diagnosed, patients should be admitted to cardiac care units for further management. Beta blocker therapy should be started within 24 hours after presentation in patients who do not have a contraindication. Contraindications include signs of heart failure, hypotension, heart conduction block, or reactive airway disease. Unless otherwise contraindicated, ACE Inhibitors should be initiated in patients with an ejection fraction less than 40%, hypertension, diabetes, or chronic kidney disease. High-dose statins should be initiated for cholesterol management. Invasive and non-invasive testing strategies are employed. Both early intervention strategies with diagnostic angiography and intervention are applied as indicated, and conservative medical management strategies are employed. The rationale for choosing one strategy over the other is often patient and institution specific and beyond the scope of this review.

Enhancing Healthcare Team Outcomes

The diagnosis and management of NSTEMI is with a multidisciplinary team that consists of a cardiologist, internist, nurse practitioner, and a pharmacist.

In patients where NSTEMI has been definitively diagnosed or is highly likely, anticoagulation should be initiated. Protocols will vary by institution, so cardiology consultation should be obtained if readily available. This is especially true when there is the possibility of percutaneous intervention, as this may change anticoagulation strategies. 

When NSTEMI has been diagnosed, patients should be admitted to cardiac care units for further management. Beta-blocker therapy should be started within 24 hours after presentation in patients who do not have a contraindication. Unless otherwise contraindicated, ACE Inhibitors should be initiated in patients with an ejection fraction less than 40%, hypertension, diabetes, or chronic kidney disease. High-dose statins should be initiated for cholesterol management. Invasive and non-invasive testing strategies are employed. Both early intervention strategies with diagnostic angiography and intervention are applied as indicated, and conservative medical management strategies are employed. 

The outcomes of patients with NSTEMI depend on the severity of myocardial injury, compliance with treatment and other comorbidity. Patients who do not change their risk factors for coronary disease have a poor outcome.[13][14] (Level V)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Non ST Segment Elevation (NSTEMI) Myocardial Infarction - Questions

Take a quiz of the questions on this article.

Take Quiz
What is a non-ST-elevation myocardial infarction myocardial infarction (MI)?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the primary difference between non-ST-segment elevation myocardial infarction and unstable angina?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is not routinely administered in patients presenting with concern for acute coronary syndrome (ACS) who have ongoing chest pain and normal vital signs?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following should be done if the diagnosis of non-ST-segment myocardial infarction is confirmed or considered highly likely?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is necessary to definitively diagnose non-ST-segment myocardial infarction?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Non ST Segment Elevation (NSTEMI) Myocardial Infarction - References

References

Gilutz H,Shindel S,Shoham-Vardi I, Adherence to NSTEMI Guidelines in the Emergency Department: Regression to Reality. Critical pathways in cardiology. 2019 Mar;     [PubMed]
Piątek Ł,Wilczek K,Janion-Sadowska A,Gierlotka M,Gąsior M,Sadowski M, Outcomes of a routine invasive strategy in elderly patients with non-ST-segment elevation myocardial infarction from 2005 to 2014: results from the PL-ACS registry. Coronary artery disease. 2019 Feb 4;     [PubMed]
Manfredonia L,Lanza GA,Crudo F,Lamendola P,Graziani F,Villano A,Locorotondo G,Melita V,Mencarelli E,Pennestrì F,Lombardo A,De Vita A,Ravenna SE,Bisignani A,Crea F, Diagnostic role of echocardiography in patients admitted to the emergency room with suspect no-ST-segment elevation acute myocardial infarction. European review for medical and pharmacological sciences. 2019 Jan;     [PubMed]
Rupprecht HJ,Geeren M,Geeren M,Weilemann S,Schuster HP, [Acute coronary syndrome without ST-elevation (NSTE-ACS)]. Herz. 2019 Feb;     [PubMed]
Kamińska J,Koper OM,Siedlecka-Czykier E,Matowicka-Karna J,Bychowski J,Kemona H, The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes. Saudi journal of biological sciences. 2018 Nov;     [PubMed]
Sriha Belguith A,Beltaief K,Msolli MA,Bouida W,Abroug H,Ben Fredj M,Zemni I,Grissa MH,Boubaker H,Hsairi M,Nouira S, Management of acute coronary syndrome in emergency departments: a cross sectional multicenter study (Tunisia). BMC emergency medicine. 2018 Dec 3;     [PubMed]
Lemkes JS,Janssens GN,van der Hoeven NW,van de Ven PM,Marques KMJ,Nap A,van Leeuwen MAH,Appelman YEA,Knaapen P,Verouden NJW,Allaart CP,Brinckman SL,Saraber CE,Plomp KJ,Timmer JR,Kedhi E,Hermanides RS,Meuwissen M,Schaap J,van der Weerdt AP,van Rossum AC,Nijveldt R,van Royen N, Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. European heart journal. 2019 Jan 14;     [PubMed]
Arora S,Stouffer GA,Kucharska-Newton A,Vaduganathan M,Qamar A,Matsushita K,Kolte D,Reynolds HR,Bangalore S,Rosamond WD,Bhatt DL,Caughey MC, Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. Journal of the American Heart Association. 2018 Oct 2;     [PubMed]
Puymirat E,Bonaca M,Fumery M,Tea V,Aissaoui N,Lemesles G,Bonello L,Ducrocq G,Cayla G,Ferrières J,Schiele F,Simon T,Danchin N, Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries. Clinical cardiology. 2019 Feb;     [PubMed]
Güntekin Ü,Tosun V,Kilinç AY,Saydam G,Korucuk N,Bozdemir MN, ST segment elevation myocardial infarction (STEMI) patients are more likely to achieve lipid-lowering treatment goals: A retrospective analysis of patients presenting with first acute coronary syndromes. Medicine. 2018 Sep;     [PubMed]
Sanchis J,Ariza-Solé A,Abu-Assi E,Alegre O,Alfonso F,Barrabés JA,Baz JA,Carol A,Díez Villanueva P,García Del Blanco B,Elízaga J,Fernandez E,García Del Egido A,García Picard J,Gómez Blázquez I,Gómez Hospital JA,Hernández-Antolín R,Llibre C,Marín F,Martí Sánchez D,Martín R,Martínez Sellés M,Miñana G,Morales Gallardo MJ,Núñez J,Pérez de Prado A,Pinar E,Sanmartín M,Sionis A,Villa A,Marrugat J,Bueno H, Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design. Revista espanola de cardiologia (English ed.). 2019 Feb;     [PubMed]
Bønaa KH,Steigen T, Coronary angiography in non-ST-elevation acute myocardial infarction - whom and when? Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2017 Nov 28;     [PubMed]
Harrington DH,Stueben F,Lenahan CM, ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction: Medical and Surgical Interventions. Critical care nursing clinics of North America. 2019 Mar;     [PubMed]
Held EP,Henry TD, When small vessels become big problems! Microvascular dysfunction in NSTEMI. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.